剖宫产瘢痕妊娠保守治疗:局部甲氨蝶呤注射后联合宫腔镜组织去除系统
本文描述一例31岁有再生育要求的剖宫产瘢痕妊娠(CSP)患者,孕9周经阴道超声提示活胎。患者选择终止妊娠,接受门诊局麻下宫腔镜局部注射甲氨蝶呤50mg,6周后再用TruClear宫腔镜组织去除系统清除无血管滋养细胞残留。两次手术分别耗时6分钟和5分钟,无并发症,1个月随访超声示瘢痕憩室空虚。
要点
- 局部甲氨蝶呤注射联合宫腔镜组织去除系统可用于有再生育要求的CSP患者。
- 该联合技术可避免能量器械所致肌层热损伤或子宫穿孔等并发症。
- 两次手术均在门诊局麻下完成,手术时间短且无术中术后并发症。
核心结论
- 局部甲氨蝶呤注射后联合宫腔镜组织去除系统清除CSP残留,可能是有近期妊娠意愿女性的有价值治疗选择。
研究设计与样本
- 技术描述并附 narrated 视频,设置于学术三级医院,患者为1例31岁有剖宫产史的女性。
主要发现
- 患者孕9周经阴道超声示前壁峡部区域妊娠囊伴活胎,提示CSP。
- 首次手术为门诊局麻下宫腔镜局部注射甲氨蝶呤50mg,手术时间6分钟。
- 6周后行宫腔镜组织去除系统清除CSP残留,手术时间5分钟。
- 两次手术均无并发症,1个月随访患者健康且超声示峡部瘢痕憩室空虚。
关键数值与推荐
- 局部甲氨蝶呤注射剂量为50mg,注射于妊娠囊种植部位周围肌层4个点及囊内6个点。
- β-人绒毛膜促性腺激素每周检测直至阴性。
- 首次术后6周行宫腔镜组织去除系统清除无血管滋养细胞残留。
临床怎么用
- 对有再生育要求的CSP患者,可考虑局部甲氨蝶呤注射后延期宫腔镜清除残留的保守联合方案。
- 该方案可在门诊局麻下完成,术中可联合经腹超声监测以降低手术风险。
局限性
- 本文为单例技术描述,未报告长期生育结局或与其他治疗方案的比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe a conservative cesarean scar pregnancy (CSP) treatment in a patient with the desire for future pregnancy. To date, there is no gold standard for the management of a viable CSP. There is a wide range of treatment options that include major surgery and minimally invasive procedures. Moreover, after a minimally invasive treatment, the gestational sac may be visible at ultrasound for >6 months. The described technique may be useful to avoid complications related to the use of energy with a large reduction in operative times. DESIGN: Description of the technique with narrated video footage. SETTING: Academic tertiary hospital. PATIENT(S): A 31-year-old woman with a previous cesarean section was referred to our clinic with lower abdominal pain. Transvaginal ultrasound revealed a gestational sac with a viable embryo located in the anterior isthmic region, suggestive of CSP at 9 weeks of gestation. Appropriate counseling describing the two diametrically opposite clinical management options was performed, and the patient decided to terminate the pregnancy. Informed consent was obtained from the patient. INTERVENTION(S): Hysteroscopy was performed under local anesthesia in an outpatient setting, using a 2.9-mm Hopkins II Forward-Oblique Telescope 30° endoscope (Karl Storz, Tuttlingen, Germany) with a 4.3-mm inner sheath and 5F instruments. A 3.7F needle (Deflux metal needle; Oceana Therapeutics, Edison, NJ) was pushed into the myometrial tissue surrounding the implantation site of the gestational sac at four different points. Six additional injections were performed into the gestational sac, and 50-mg methotrexate was injected. The appropriate follow-up was performed to determine the success of the procedure. β-Human chorionic gonadotropin was dosed weekly until negative. After 6 weeks, to remove the avascular trophoblastic remnants found at ultrasound evaluation, the patient underwent hysteroscopic removal with a 6-mm TruClear hysteroscopic tissue removal system (Medtronic Parkway, Minneapolis, MN). A contemporary transabdominal ultrasound was performed to minimize surgical risks. MAIN OUTCOME MEASURE(S): Complete and conservative CSP treatment with the absence of surgical complications. RESULT(S): Conservative cesarean scar pregnancy treatment was performed successfully with primary local methotrexate injection followed, after 6 weeks, by hysteroscopic removal of the CSP remnants with the TruClear hysteroscopic tissue removal system. The first procedure lasted 6 minutes, whereas hysteroscopic removal of the CSP lasted 5 minutes. Both procedures were performed in an outpatient setting, and no complications were detected during and after the treatments. The patient reported good health at the 1-month follow-up visit, and the ultrasound showed an empty isthmocele (Fig. 1). CONCLUSION(S): Primary local methotrexate injection followed by hysteroscopic removal of the CSP remnants with the hysteroscopic tissue removal system may be a valuable treatment for women who desire pregnancy in the near future. This combined technique may avoid potential complications, such as thermal-induced myometrial injuries or uterine perforation. Moreover, the operator has the possibility to perform an under-vision procedure with a lower incidence of intraoperative and postoperative bleeding. Because it does not reduce fertility/pregnancy rate, this technique should be a valid option in patients who desire future pregnancy.
引用
- Casadio P, Ambrosio M, Verrelli L, et al. Conservative cesarean scar pregnancy treatment: local methotrexate injection followed by hysteroscopic removal with hysteroscopic tissue removal system. Fertil Steril. 2021. PMID: 34289934. doi:10.1016/j.fertnstert.2021.06.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。